论文部分内容阅读
目的:观察2型糖尿病患者应用罗格列酮治疗前、后血清C反应蛋白水平变化,探讨罗格列酮的抗炎作用。方法:2型糖尿病患者42例均给予罗格列酮4 mg/d,1次/d,口服,疗程6个月,比较治疗前、后糖化血红蛋白、C反应蛋白、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、三酰甘油水平。结果:治疗后糖化血红蛋白(7.31±0.21)%较治疗前(8.39±0.26)%降低(P<0.01),C反应蛋白水平(19.2±1.7)mg/L较治疗前(60.5±8.1)mg/L降低(P<0.01);治疗前、后高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、三酰甘油水平比较差异无统计学意义(P>0.05)。结论:罗格列酮可降低2型糖尿病患者血清C反应蛋白水平,具有抗炎作用。
OBJECTIVE: To observe the changes of serum C-reactive protein level before and after rosiglitazone treatment in type 2 diabetic patients and to explore the anti-inflammatory effect of rosiglitazone. Methods: Forty-two patients with type 2 diabetes were treated with rosiglitazone 4 mg once daily for 6 months. The levels of HbA1c, C-reactive protein, high density lipoprotein cholesterol, Density lipoprotein cholesterol, triglyceride levels. Results: After treatment, the HbA 1c (7.31 ± 0.21)% was lower than that before treatment (8.39 ± 0.26)% and the level of C - reactive protein (19.2 ± 1.7) mg / L was (60.5 ± 8.1) mg / L (P <0.01). There was no significant difference in the levels of HDL, LDL-C and triglyceride before and after treatment (P> 0.05). Conclusion: Rosiglitazone can reduce the level of serum C-reactive protein in patients with type 2 diabetes and has anti-inflammatory effects.